Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 52-Week Low - Should You Sell?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $12.14 and last traded at $12.74, with a volume of 2848318 shares traded. The stock had previously closed at $13.82.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ARWR. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a "sell" rating in a research report on Friday, December 20th. HC Wainwright reiterated a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. B. Riley reissued a "buy" rating and issued a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Arrowhead Pharmaceuticals has a consensus rating of "Hold" and an average price target of $41.44.

Remove Ads

Arrowhead Pharmaceuticals Price Performance

The company has a 50-day moving average price of $17.31 and a 200-day moving average price of $19.31. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of -2.07 and a beta of 0.92. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.97). On average, equities research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, CFO Kenneth Allen Myszkowski sold 27,167 shares of the company's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $19.83, for a total value of $538,721.61. Following the completion of the transaction, the chief financial officer now owns 473,433 shares in the company, valued at $9,388,176.39. This represents a 5.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Christopher Richard Anzalone sold 51,425 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $15.07, for a total transaction of $774,974.75. Following the completion of the sale, the chief executive officer now directly owns 4,062,377 shares in the company, valued at $61,220,021.39. This represents a 1.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 274,797 shares of company stock valued at $4,830,279. Company insiders own 4.30% of the company's stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Mackenzie Financial Corp bought a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter worth approximately $137,000. GF Fund Management CO. LTD. bought a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at $49,000. Neo Ivy Capital Management bought a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at $318,000. Two Sigma Advisers LP increased its stake in Arrowhead Pharmaceuticals by 330.7% in the 4th quarter. Two Sigma Advisers LP now owns 430,700 shares of the biotechnology company's stock valued at $8,097,000 after buying an additional 330,700 shares during the last quarter. Finally, Two Sigma Investments LP lifted its position in Arrowhead Pharmaceuticals by 281.3% during the 4th quarter. Two Sigma Investments LP now owns 794,373 shares of the biotechnology company's stock worth $14,934,000 after buying an additional 586,062 shares in the last quarter. Institutional investors and hedge funds own 62.61% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.